FENC

FENC Uncaps Major Success with Global Sustainable Expansion in Recycled Polyester

Retrieved on: 
金曜日, 5月 3, 2024
P&G, Suntory, Adidas, Risk, Pepsi, L'Oréal, Biophysical environment, Testament, PET, F&N, Corporate welfare, Sustainalytics, FENC, Nike, Ivivva athletica, Fiji Water, ESG, Food, Coca-Cola, Asahi, Recycling

TAIPEI, May 3, 2024 /PRNewswire/ -- Far Eastern New Century (FENC) leads global sustainable recycled polyester industry.

Key Points: 
  • TAIPEI, May 3, 2024 /PRNewswire/ -- Far Eastern New Century (FENC) leads global sustainable recycled polyester industry.
  • Through FENC's vast recycling capacity, FENC  recycle over 22 billion pcs of post-consumer recycled PET bottles into a high quality  sustainable products.
  • To bolster its leadership and propel the polyester sector towards greener pastures, FENC is actively expanding its capacity for high-value food-grade recycled polyester.
  • Moreover, in Malacca, Malaysia, FENC broke ground on an expansion project for its recycled polyester factory in April 2024.

FENC Uncaps Major Success with Global Sustainable Expansion in Recycled Polyester

Retrieved on: 
金曜日, 5月 3, 2024
P&G, Suntory, Adidas, Risk, Pepsi, L'Oréal, Biophysical environment, Testament, PET, F&N, Corporate welfare, Sustainalytics, FENC, Nike, Ivivva athletica, Fiji Water, ESG, Food, Coca-Cola, Asahi, Recycling

TAIPEI, May 3, 2024 /PRNewswire/ -- Far Eastern New Century (FENC) leads global sustainable recycled polyester industry.

Key Points: 
  • TAIPEI, May 3, 2024 /PRNewswire/ -- Far Eastern New Century (FENC) leads global sustainable recycled polyester industry.
  • Through FENC's vast recycling capacity, FENC  recycle over 22 billion pcs of post-consumer recycled PET bottles into a high quality  sustainable products.
  • To bolster its leadership and propel the polyester sector towards greener pastures, FENC is actively expanding its capacity for high-value food-grade recycled polyester.
  • Moreover, in Malacca, Malaysia, FENC broke ground on an expansion project for its recycled polyester factory in April 2024.

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
木曜日, 3月 21, 2024
AYA, Research, Remuneration, Civil service commission, Administration, Conference, Net, Growth, Young adult, Fennec, FENC, Patient, Into, G&A, NCCN, Adolescence, Marketing, MHRA, TSX, European Commission, FDA, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2023 and provided a business update.

Key Points: 
  • ET ~
    RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2023 and provided a business update.
  • PEDMARQSI was granted EU marketing authorization by the European Commission in June 2023, and received UK approval from the MHRA in October 2023.
  • Achieved PEDMARK net product revenue of approximately $9 million and $21 million for the fourth quarter and full year 2023, respectively.
  • Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023
    Net Sales – Net product sales of $21.3 million in fiscal 2023 compared to $1.5 million in 2022.

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Retrieved on: 
月曜日, 3月 18, 2024
Civil service commission, Neuroblastoma, Ototoxicity, Partnership, Central nervous system, ANZ, Risk, FENC, Patient, Hepatoblastoma, Neoplasm, Cancer, MHRA, TSX, Hearing loss, European, Cisplatin, Safety, European Commission, Liver, Arnold & Porter, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C. and UXBRIDGE, United Kingdom, March 17, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to

Key Points: 
  • Norgine will be responsible for all commercialization activities in the licensed territories and will hold all marketing authorizations in the licensed territories.
  • It is estimated that more than 5,000 pediatric patients annually are eligible for platinum-based chemotherapy in Europe.
  • PEDMARQSI was granted EU marketing authorization by the European Commission in June 2023, and received UK approval from the MHRA in October 2023.
  • The studies compared PEDMARQSI plus cisplatin-based regimens to cisplatin-based regimens alone for the reduction of cisplatin-induced hearing loss in pediatric patients.

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Retrieved on: 
月曜日, 3月 18, 2024
Civil service commission, Neuroblastoma, Ototoxicity, Partnership, Central nervous system, ANZ, Risk, FENC, Patient, Hepatoblastoma, Neoplasm, Cancer, MHRA, TSX, Hearing loss, European, Cisplatin, Safety, European Commission, Liver, Arnold & Porter, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C. and UXBRIDGE, England, March 18, 2024 /PRNewswire/ -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to

Key Points: 
  • Norgine will be responsible for all commercialization activities in the licensed territories and will hold all marketing authorizations in the licensed territories.
  • It is estimated that more than 5,000 pediatric patients annually are eligible for platinum-based chemotherapy in Europe.
  • The studies compared PEDMARQSI plus cisplatin-based regimens to cisplatin-based regimens alone for the reduction of cisplatin-induced hearing loss in pediatric patients.
  • Moelis & Company LLC acted as financial advisor, and LaBarge Weinstein LLP acted as legal advisor to Fennec.

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
木曜日, 2月 29, 2024
Incidence, Osteosarcoma, Fennec, FDA, TSX, Food, Neuroblastoma, Germ cell tumor, Hepatoblastoma, Risk, Literacy, Safety, Audit, Cisplatin, Hearing loss, Medulloblastoma, Kool-Aid, Ototoxicity, Food and Drug Administration, Patient, Survival, FENC, COG

RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced preliminary unaudited fourth quarter and full-year 2023 net revenues.

Key Points: 
  • ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~
    RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced preliminary unaudited fourth quarter and full-year 2023 net revenues.
  • The information in this press release is based upon preliminary unaudited information and management estimates for the fourth quarter 2023 and is subject to the completion of Fennec’s financial closing procedures and year end audit.
  • Preliminary Unaudited 2023 Fourth Quarter Revenue and Year End Performance:
    Fourth quarter 2023 net revenues are expected to be approximately $9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023.
  • Fennec expects to report its 2023 fourth quarter and audited full-year year results of operations on or about March 26, 2024.

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Retrieved on: 
木曜日, 2月 1, 2024
Hypothermia, Sodium nitrite, Fatigue, Ototoxicity, Cisplatin, Patient, FENC, STS, FDA, Restless, Kidney, TSX, Argyreia nervosa, Communication, Food, Methemoglobinemia, Risk, Dermatitis, Headache, Potassium chloride, Pharmaceutical industry

PEDMARK is the first and only FDA approved therapy indicated to reduce the risk of ototoxicity (e.g., permanent hearing loss) associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Key Points: 
  • PEDMARK is the first and only FDA approved therapy indicated to reduce the risk of ototoxicity (e.g., permanent hearing loss) associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.
  • The FDA reminded health care providers that as stated in PEDMARK’s prescribing information , PEDMARK is not substitutable with other sodium thiosulfate products.
  • Sodium nitrite is co-packaged with sodium thiosulfate as a separate vial in some products; it is not present in PEDMARK.
  • The FDA encourages those with any questions to contact [email protected].

Fennec Announces Incremental $5 Million Investment from Petrichor

Retrieved on: 
火曜日, 12月 5, 2023
Petrichor, Risk, Sale, Hearing loss, Survivor, Cancer, TSX, FENC, Patient

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company focused on improving the lives of children with cancer, today announced the third closing of $5 million senior secured promissory notes under the existing agreement with Petrichor. The original investment agreement provided access to up to $20 million of additional financing through December 31, 2023. As part of this closing, Fennec and Petrichor have amended the agreement to provide access to up to $15 million of additional financing through December 31, 2024.

Key Points: 
  • The original investment agreement provided access to up to $20 million of additional financing through December 31, 2023.
  • As part of this closing, Fennec and Petrichor have amended the agreement to provide access to up to $15 million of additional financing through December 31, 2024.
  • “We appreciate Petrichor’s continued support of Fennec and our efforts to grow the use of PEDMARK within the global pediatric cancer community,” said Rosty Raykov, Chief Executive Officer of Fennec.
  • Survivors of pediatric cancer should not have to additionally suffer treatment-induced hearing loss in cases where it can be safely avoided.

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
木曜日, 11月 9, 2023
Cisplatin, Literacy, Food and Drug Administration, Neuroblastoma, FENC, Safety, COG, Food, GMT, Ototoxicity, Incidence, Risk, Patient, Medulloblastoma, FDA, Hepatoblastoma, Conference, Kool-Aid, Germ cell tumor, Survival, Hearing loss, RESEARCH, Osteosarcoma, TSX, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.
  • The management team will also host one-on-one investor meetings at the conferences.
  • Event: Jefferies London Healthcare Conference in London, UK
    Time: Company Presentation at 5:00 a.m.
  • It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients.

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
月曜日, 11月 6, 2023
Research, Adolescence, Research and development, Medicines and Healthcare products Regulatory Agency, PIN, FENC, Medication, RESEARCH, G&A, Conference, AYA, Remuneration, R, Software, Bank statement, News, Growth, MHRA, Marketing, Webcast, Young adult, NCCN, PARK, Calendar, Administration, TSX, Pharmaceutical industry, Cryptocurrency

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today reported its financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • ET ~
    RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today reported its financial results for the third quarter ended September 30, 2023 and provided a business update.
  • “We continued to see strong commercial performance with PEDMARK® in the third quarter demonstrated by net product revenue of $6.5 million representing 96% quarter over quarter growth.
  • The Company had gross profit of $6.2 million for the third quarter of 2023.
  • ET, to discuss the Company’s financial results from the third quarter, ended September 30, 2023, and provide a business outlook for the remainder of 2023.